Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients With Clear Cell mRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients With Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
Oncologist 2020 Jan 23;[EPub Ahead of Print], MF Savard, JC Wells, J Graham, S Dudani, JA Steinharter, BA McGregor, F Donskov, GA Bjarnason, UN Vaishampayan, AR Hansen, MAJ Iafolla, G Zanotti, L Huynh, R Chang, MS Duh, DYC HengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.